MA33084B1 - Peptides inhibant le facteur de nécrose tumorale alpha et leurs utilisations - Google Patents

Peptides inhibant le facteur de nécrose tumorale alpha et leurs utilisations

Info

Publication number
MA33084B1
MA33084B1 MA33940A MA33940A MA33084B1 MA 33084 B1 MA33084 B1 MA 33084B1 MA 33940 A MA33940 A MA 33940A MA 33940 A MA33940 A MA 33940A MA 33084 B1 MA33084 B1 MA 33084B1
Authority
MA
Morocco
Prior art keywords
necrosis factor
tumor necrosis
tnf
alpha
inhibiting alpha
Prior art date
Application number
MA33940A
Other languages
Arabic (ar)
English (en)
Inventor
Rajesh Jain
Virendra Kumar Vinayak
Shweta Dubey
Sudhanand Prasad
Vijay Goel
Rahul Jain
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of MA33084B1 publication Critical patent/MA33084B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/123—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des peptides inhibant le facteur de nécrose tumorale alpha (TNF-alpha ou TNF-±) et leur procédé de préparation. La présente invention concerne également une composition pharmaceutique qui comprend lesdits peptides inhibant le TNF-alpha et des utilisations associées pour traiter des troubles inflammatoires à médiation assurée par le TNF-alpha.
MA33940A 2008-11-20 2009-11-05 Peptides inhibant le facteur de nécrose tumorale alpha et leurs utilisations MA33084B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2622DE2008 2008-11-20
PCT/IN2009/000626 WO2010058419A1 (fr) 2008-11-20 2009-11-05 Peptides inhibant le facteur de nécrose tumorale alpha et leurs utilisations

Publications (1)

Publication Number Publication Date
MA33084B1 true MA33084B1 (fr) 2012-03-01

Family

ID=42197885

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33940A MA33084B1 (fr) 2008-11-20 2009-11-05 Peptides inhibant le facteur de nécrose tumorale alpha et leurs utilisations

Country Status (16)

Country Link
US (1) US20120010158A1 (fr)
EP (1) EP2362880A1 (fr)
JP (1) JP2012509312A (fr)
KR (1) KR20110093899A (fr)
CN (1) CN102282163A (fr)
AR (1) AR074388A1 (fr)
AU (1) AU2009318779A1 (fr)
CA (1) CA2744365A1 (fr)
CO (1) CO6362019A2 (fr)
IL (1) IL213026A0 (fr)
MA (1) MA33084B1 (fr)
MX (1) MX2011005363A (fr)
PE (1) PE20110708A1 (fr)
RU (1) RU2011151260A (fr)
SG (1) SG171348A1 (fr)
WO (1) WO2010058419A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016190660A1 (fr) * 2015-05-26 2016-12-01 주식회사 젬백스앤카엘 Nouveau peptide et composition le contenant
GB201510758D0 (en) * 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
CN106831944A (zh) * 2017-01-12 2017-06-13 复旦大学 一种肿瘤坏死因子alpha的高亲和性肽及其应用
CN107383174B (zh) * 2017-08-21 2019-01-18 生工生物工程（上海）股份有限公司 一种能与pd-1特异性结合的肿瘤抑制肽及其用途
JP7398716B2 (ja) * 2019-11-05 2023-12-15 国立大学法人京都大学 ペプチド、組成物、及び、気分障害を治療、予防、又は改善する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026744A1 (fr) * 1994-04-01 1995-10-12 Centocor, Inc. Inhibiteurs du facteur de necrose tumorale
US5753628A (en) * 1995-06-07 1998-05-19 Centocor, Inc. Peptide inhibitors of TNF containing predominantly D-amino acids
WO2005030798A2 (fr) * 2003-09-24 2005-04-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Agents inhibiteurs et agents stimulateurs de l'enzyme de conversion du tnf-$g(a)

Also Published As

Publication number Publication date
CN102282163A (zh) 2011-12-14
SG171348A1 (en) 2011-07-28
CO6362019A2 (es) 2012-01-20
AR074388A1 (es) 2011-01-12
MX2011005363A (es) 2011-08-12
EP2362880A1 (fr) 2011-09-07
IL213026A0 (en) 2011-07-31
JP2012509312A (ja) 2012-04-19
KR20110093899A (ko) 2011-08-18
CA2744365A1 (fr) 2010-05-27
WO2010058419A4 (fr) 2010-07-29
US20120010158A1 (en) 2012-01-12
RU2011151260A (ru) 2013-06-20
WO2010058419A1 (fr) 2010-05-27
AU2009318779A1 (en) 2011-07-07
PE20110708A1 (es) 2011-10-23

Similar Documents

Publication Publication Date Title
MX2024000208A (es) Restos de administracion terapeutica novedosos y usos de estos.
MA33084B1 (fr) Peptides inhibant le facteur de nécrose tumorale alpha et leurs utilisations
MA30358B1 (fr) Quinazolines pour l'inhibition de pdk1
JP2016515134A5 (fr)
AU2017258105A1 (en) Methods for treating patients with familial hypercholesterolemia
MX2022016427A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
TW200720272A (en) Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
WO2007015866A3 (fr) Inhibiteurs de la p38 kinase et procédés de traitement d’affections inflammatoires
MX2008012479A (es) Tratamiento de enfermedades neurodegenerativas.
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
EA200970349A1 (ru) Ингибиторы металлопротеазы гетероциклического происхождения
MX2008011175A (es) Inhibidores de fosfodiesterasa 10.
WO2007015877A3 (fr) Inhibiteurs de la p38 kinase et procedes permettant de traiter les troubles inflammatoires
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
EA201001085A1 (ru) Фармацевтические композиции, содержащие гранулы очищенной микробной липазы, и способы предупреждения или лечения пищеварительных нарушений
MA38161A1 (fr) Anticorps anti-bmp-6
WO2012128521A3 (fr) Composition pharmaceutique destinée à traiter des maladies associées au vieillissement, contenant comme principe actif un inhibiteur de l'expression de la progérine, et procédé de criblage à la recherche dudit inhibiteur de l'expression de la progérine
MA41985B1 (fr) Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux
MX2021008507A (es) Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas.
TW200628473A (en) Novel heterocycles
TW200716172A (en) Pharmaceutical compositions for treating lower motor neuron diseases
MX2008001982A (es) Compuestos nitro-o, sus composiciones farmaceuticas y sus usos.